-+ 0.00%
-+ 0.00%
-+ 0.00%

Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9

PUBT·09/04/2026 12:01:11
Listen to the news
Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9
  • Tyra Biosciences scheduled a Sept. 9, 2026 conference call to present initial Phase 2 results for oral dabogratinib.
  • Data will be presented in the future, covering the SURF302 study in intermediate-risk non-muscle invasive bladder cancer.
  • The update signals an early readout for a key clinical program targeting FGFR biology, a potential driver of future development decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609040800PR_NEWS_USPR_____LA40038) on September 04, 2026, and is solely responsible for the information contained therein.